For Q4 2025, Exact Sciences generated revenue of 878381000, up 23% year-over-year, driven by Screening revenue of 695138000 and Precision Oncology revenue of 183243000. The company reported a net loss of 85955000, or 0.45 per share, and adjusted EBITDA of 63441000 with a 7% margin.
Total revenue increased 23% year-over-year to 878381000.
Screening revenue grew 26% to 695138000, while Precision Oncology increased 14% to 183243000.
Gross margin was 70%, and adjusted gross margin was 73%.
Adjusted EBITDA was 63441000 with a 7% margin, while net loss totaled 85955000.
Exact Sciences highlighted continued growth momentum across its core products and pipeline expansion, while the pending merger with Abbott remains subject to regulatory approval and stockholder vote.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance